共 76 条
[1]
Soler D(2009)The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases J Pharmacol Exp Ther 330 864-875
[2]
Chapman T(2012)Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study Inflamm Bowel Dis 18 1470-1479
[3]
Yang LL(2013)Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 699-710
[4]
Wyant T(2013)Vedolizumab as induction and maintenance therapy for Crohn’s disease N Engl J Med 369 711-721
[5]
Egan R(2014)Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 618-627
[6]
Fedyk ER(2015)Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease Aliment Pharmacol Ther 42 188-202
[7]
Parikh A(2005)Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin N Engl J Med 352 2499-2507
[8]
Leach T(2008)Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin Clin Gastroenterol Hepatol. 6 1370-1377
[9]
Wyant T(2012)Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study Inflamm Bowel Dis 18 1470-1479
[10]
Scholz C(2016)Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab Cytom B Clin Cytom 90 168-176